Could a Mucus-Busting drug help Hard-to-Treat asthma?
NCT ID NCT03994380
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small pilot study tested whether inhaling a drug called rhDNAse every day for 4 weeks could help adults with neutrophilic asthma, a type of asthma that often doesn't respond well to standard treatments. The drug works by breaking down DNA in lung mucus, making it thinner and easier to cough up. Researchers measured changes in lung function and asthma symptom control to see if the treatment was beneficial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rhDNAse (a drug that breaks down DNA in mucus, making it easier to clear from the lungs)
- What this could lead to
- If it works, this could point toward a new way to ease breathing and control symptoms for people with neutrophilic asthma.
- What could go wrong
- This is a very small, early-phase pilot study with only 19 participants, so results may not apply to everyone. The drug may not improve lung function or symptoms as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUTROPHILIC ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Jewish Health
Denver, Colorado, 80206, United States